Previous Article | Next Article ![]()
Infection and Immunity, January 2008, p. 198-205, Vol. 76, No. 1
0019-9567/08/$08.00+0 doi:10.1128/IAI.01139-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Department of Oral Biology, School of Dental Medicine, State University of New York at Buffalo, Buffalo, New York 14214,1 Center for Oral Health and Systemic Disease, Department of Periodontics, Endodontics and Dental Hygiene, University of Louisville School of Dentistry, Louisville, Kentucky 402922
Received 17 August 2007/ Returned for modification 24 September 2007/ Accepted 20 October 2007
|
|
|---|
|
|
|---|
We previously identified a cell surface-associated and secreted protein with pathogenic attributes, designated BspA, from T. forsythia (26). The BspA protein is characterized by the presence of two leucine-rich repeat (LRR) domains separated by a short segment in the N-terminal region of the molecule. The LRR domains are thought to function in binding to other proteins via protein-protein interactions (16, 17). In addition, the BspA protein contains two tandem immunoglobulin (Ig)-like domains in the C-terminal region. Recent studies in our laboratory have suggested multiple virulence functions for BspA which are likely to play significant roles in periodontitis. In this regard, in vitro studies have shown that BspA triggers release of proinflammatory cytokines from human monocytic THP-1 cells (6), as well as release of chemokines from murine osteoblasts (24), and BspA is required for uptake of T. forsythia by epithelial cells in vitro (12). The bacterial uptake is dependent upon host protein phosphorylation in response to interactions of BspA with a cellular receptor(s). Additionally, we have shown that periodontitis patients harboring T. forsythia elicit BspA-specific serum antibodies (26) and that BspA expression is required for alveolar bone loss in mice, indicating an in vivo role for BspA as well (25). Further, analysis of the recently completed draft sequence of the T. forsythia genome deposited in the Los Alamos oral pathogen database (www.oralgen.lanl.gov) has indicated the presence of multiple BspA-like homolog proteins in T. forsythia.
Toll-like receptors (TLRs) recognize a variety of microbe-associated molecular patterns and trigger innate immunity, and they also play an instructive role in the induction of the adaptive immunity (29). In general, different TLRs recognize distinct microbial structures. For example, TLR2 responds to lipid moieties and peptides, TLR4 responds to lipopolysaccharide (LPS), and TLR5 responds to flagellin. In this regard, T. forsythia and other gram-negative periodontal bacteria have been shown to activate TLR2 (15). Antibody inhibition data obtained by our group have suggested that TLR2 may be involved in BspA-induced release of proinflammatory cytokines by the human monocytic cell line THP-1 (6). This may represent a mechanism by which T. forsythia induces periodontal inflammation. Although macrophages are considered to be key players in innate immunity, since they are phagocytic cells as well as targets for activation by T cells, epithelial cells also play essential roles in providing innate defense against microbial challenge through the production of antimicrobial molecules, as well as cytokines and chemokines necessary for leukocyte recruitment (14). The overall objectives of this study were to determine if BspA is involved in epithelial cell activation leading to chemokine secretion and to elucidate the mechanism involved in this activation. Importantly, we were interested in determining the role of TLRs in BspA-mediated activation of epithelial cells. Our findings show that the BspA LRR domains are involved in the activation of epithelial cells via TLR2 binding. In addition, we demonstrated that TLR1 cooperates with TLR2 in the activation of epithelial cells in response to BspA.
|
|
|---|
Bacteria and rBspA.
T. forsythia parent strain ATCC 47037 and a BspA-defective mutant of this strain were grown using previously described culture conditions (11), Briefly, T. forsythia ATCC 43037 was grown anaerobically (5% CO2, 10% H2, 85% N2) in brain heart infusion (Difco Laboratories, Detroit, MI) broth containing 5 µg/ml hemin, 0.5 µg/ml menadione, 0.001% N-acetylmuramic acid, and 5% fetal bovine serum (Life Technologies, Grand Island, NY). The BspA-deficient mutant BFM571 (11) was grown anaerobically in the same medium containing 5 µg/ml tetracycline. The full-length and truncated polypeptides of BspA were expressed as His-tagged fusion proteins in E. coli utilizing the pQE80 expression plasmid system (Qiagen, Valencia, CA). The recombinant polypeptides included (Fig. 1A) recombinant BspA (rBspA) (residues 17 to 1081 of the mature protein), rBspLRR-1-2 (residues 17 to 726, including both LRR domains, domains D1 and D2), rBspLRR-1 (residues 17 to 419, including only the D1 domain), and rBsp
LRR (residues 727 to 1081, containing only the C-terminal Big_2 region). The DNA fragments encoding these recombinant polypeptides were amplified from T. forsythia genomic DNA using forward primer 5'-GCGCGGATCCTTGACGACCCTGGGCGCTACGGC-3' and reverse primer 5'-GCCCAAGCTTTCACTTTATAAGAATTTTGGTTACCCG-3' (rBspA) or the same forward primer and either reverse primer 5'-GCCCAAGCTTTCAGGCGTCAACGAAGGAGAGC-3' (rBspLRR-1-2) or reverse primer 5'-GCCCAAGCTTTCATACGGTCACGTCCTT-3' (rBspLRR-1). The DNA fragment encoding the rBsp
LRR polypeptide was amplified with forward primer 5'-GCGCGGATCCGGCGGAACGAAGCCGATCAC-3' and reverse primer 5'-GCCCAAGCTTTCACTTTATAAGAATTTTGGTTACCCG-3'. The underlined residues indicate a BamHI restriction site and a HindIII restriction site in the forward and reverse primers, respectively. The amplified DNA fragments were cloned into the BamH-HindIII site of the pQE80 plasmid vector, and sequences of the inserts were confirmed by DNA sequencing at the DNA Core Facility at Roswell Park Cancer Institute (Buffalo, NY) to confirm correct in-frame cloning. All plasmids were introduced into E. coli BL21 (Novagen, Madison, WI). Expression of recombinant polypeptides was induced with isopropyl-β-D-thiogalactoside, and the recombinant BspA polypeptides were purified from the soluble extracts of E. coli by affinity chromatography using a His·Bind resin column (Novagen). The purity of the recombinant proteins was confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. All protein preparations were also analyzed by quantitative Limulus amebocyte lysate assays (using kits obtained from BioWhittaker, Walkersville, MD, or from Charles River Endosafe, Charleston, SC) to measure incidental endotoxin contamination. All polypeptide preparations were essentially free of LPS (
0.0064 ng/µg of protein). A His-glutathione S-transferase fusion protein (His-GST) was likewise expressed and purified, and it was used as a negative control in epithelial cell activation assays. The purity of recombinant proteins was confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (Fig. 1B) and quantitative Limulus amebocyte lysate assays (using kits obtained from BioWhittaker, Walkersville, Md., or Charles River Endosafe, Charleston, SC) to determine endotoxic activity. All BspA preparations were essentially free of incidental LPS contamination (
0.0064 ng/µg of protein). All recombinant BspA polypeptides were treated further with polymyxin B (10 mg/ml) to block any undetectable LPS in the preparation. Preliminary experiments showed that there was no significant cytokine induction with polymyxin B at a concentration of 10 µg/ml compared to a no-stimulation control in human gingival epithelial cells (HGECs) or even in primary monocytic cells (data not shown).
![]() View larger version (26K): [in a new window] |
FIG. 1. (A) Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of rBspA and its derivatives. Lane stnd, protein marker; lane 1, rBspA; lane 2, rBspLRR-1-2; lane 3, rBspLRR-1; lane 4, rBsp LRR; lane 5, His-GST. The numbers on the left indicate the molecular masses of protein standards. (B) Schematic diagrams of BspA and its truncated derivatives expressed as recombinant proteins. The amino acid residues for each derivative are indicated in parentheses. Abbreviations: D1, LRR domain D1 containing 14 tandem LRRs (residues 91 to 412); D2, LRR domain D2 containing six tandem LRRs; Big_2, bacterial Ig-like domains.
|
Transient transfection and luciferase assay.
HEK293 cells were seeded at a concentration of 6 x 104 cells per well in a 48-well plate. After incubation until they reached about 60% confluence, HEK293 cells were transiently transfected with the indicated TLR plasmids and simultaneously cotransfected with a firefly luciferase gene conjugated with the NF-
B promoter as a reporter gene and pRL-TK containing a Renilla luciferase gene as an internal control (Promega, Madison, WI). Transfection was performed using the FuGENE 6 transfection reagent at a reagent-to-DNA ratio of 3:1 (vol/wt) (Roche Diagnostics, Indianapolis, IN) according to the manufacturer's instructions. The total amount of transfected plasmid DNA was equalized by supplementation with an empty vector, pFLAG-CMV. Polymyxin B sulfate (10 µg/ml) was added to each recombinant protein prior to stimulation to block any contaminating LPS in the preparation. At 24 h posttransfection, the cells were stimulated with the indicated reagents for 6 h, and cells were collected for further analysis. Firefly luciferase and Renilla luciferase activities were determined using dual-luciferase reporter assay systems (Promega) according to the manufacturer's instructions. The firefly luciferase activity was normalized to that of Renilla luciferase to correct the transfection efficiency and cell viability.
BspA binding to TLR2. TLR2 binding was measured as previously described (18). Briefly, 96-well microtiter wells were coated overnight at 4°C with 20 µg/ml of purified recombinant mouse TLR2 (R&D Systems, Minneapolis, MN). After washing and blocking of nonspecific binding sites, biotinylated BspA (2.5 to 40 µg/ml in phosphate-buffered saline [PBS] containing 1% bovine serum albumin) was incubated for 2 h at 37°C. After washing, bound protein was detected with peroxidase-conjugated streptavidin. Alternatively, nonbiotinylated BspA was used, and bound protein was detected with specific IgG anti-BspA antibody followed by peroxidase-conjugated goat anti-rabbit IgG (adsorbed against human or mouse IgG). The peroxidase reaction was performed using the 3,3',5,5'-tetramethylbenzidene chromogenic substrate, and the optical density at 450 nm was determined with a microplate reader (Bio-Tek Instruments, Winooski, VT). The dissociation constant (Kd) was calculated using GraphPad Prism-4 software based on the law of mass action, according to which the Kd (in moles per liter) equals the concentration of ligand which occupies one-half of the receptors at equilibrium.
Epithelial cells. Following approval by the University of Louisville Institutional Review Board, primary HGECs were obtained from healthy patients after third-molar extraction as described previously (3). Briefly, the HGECs were grown in serum-free keratinocyte medium (Invitrogen, Carlsbad, CA) containing 10 µg/ml of insulin, 5 µg/ml of transferrin, 10 µM 2-mercaptoethanol, 10 µM 2-aminoethanol, 10 nM sodium selenite, 50 µg/ml of bovine pituitary extract, 100 U/ml of penicillin/streptomycin, and 50 ng/ml of amphotericin B (complete medium). The cells were seeded in 60-mm-diameter plastic tissue culture dishes coated with type I collagen and incubated in 5% CO2-95% air at 37°C. When the cells reached 80% confluence, they were harvested and subcultured in complete medium. HEK293 cells were cultured in Dulbecco's modified Eagle's medium (Mediatech Inc.) supplemented with 10% fetal bovine serum (Gibco, Carlsbad, CA) and 1% Antibiotic-Antimycotic (Gibco). HEK293 (hTLR2/hTLR1) cells stably expressing human TLR2 and human TLR1 were purchased from InvivoGen (San Diego, CA). These cells were cultured in normal growth medium supplemented with 0.1% blasticidin (InvivoGen).
Cytokine ELISA. HGECs were plated on 96-well plates at a concentration of 2 x 105 cells per well containing 100 µl of normal growth medium. The cells were grown for 4 days to obtain confluence prior to challenge. At 24 h prior to challenge, the cells were washed with PBS and 100 µl of fresh normal growth medium was added to the wells. Cells were preincubated with anti-TLR2 MAb (TL2.1) or an Ig isotype-matched control (IgG2a) for 30 min and then incubated with Pam3Cys or BspA for 16 h at 37°C in humidified air containing 5% (vol/vol) CO2. HEK293 (hTLR2/hTLR1) or HEK293 cells were plated on 24-well plates at a concentration of 1 x 105 cells per well in 500 µl of normal growth medium. The cells were grown to confluence and then washed with PBS, and 500 µl of fresh Dulbecco's modified Eagle's medium with 2.5% fetal bovine serum was added to the wells. Cells were treated with Pam3Cys or rBspA for 16 h. The culture supernatants were collected, clarified by centrifugation, diluted 1:50 or 1:100, and stored at –70°C until they were assayed. The culture supernatants were assayed for interleukin-1β (IL-1β) and IL-6 (eBioscience, San Diego, CA) and for IL-8 (Pelikine, Sanquin, Amsterdam, The Netherlands) by performing enzyme-linked immunosorbent assays (ELISAs) as directed by the manufacturer.
|
|
|---|
|
View this table: [in a new window] |
TABLE 1. BspA stimulates proinflammatory cytokine expression in HGECs
|
![]() View larger version (34K): [in a new window] |
FIG. 2. IL-8 induction in epithelial cells challenged with the BspA protein. HGECs were treated with rBspA (5 µg/ml) or the TLR2 agonist Pam3Cys (Pam3) (0.1 µg/ml) for 6 h. Induction of IL-8 in culture supernatants was determined by an ELISA. The data are the means ± standard deviations of triplicate determinations in one of three independent sets of experiments that yielded similar findings. Statistically significant (P < 0.05) blocking of cytokine release by TLR2 antibody (Ab) is indicated by an asterisk.
|
B in human embryonic kidney (HEK293) cells transiently expressing different TLRs alone or in combination. Briefly, HEK293 cells were transiently transfected with a TLR1, -2, -4, or -6-expressing plasmid along with an NF-
B promoter-conjugated luciferase reporter plasmid. Transfected HEK293 cells were then used to determine the abilities of zymosan (a TLR2 agonist), highly purified E. coli LPS (a TLR4 agonist), or BspA to induce NF-
B activation. HEK293 cells transfected with pCMV4 alone were used as a control. Both zymosan and BspA activated NF-
B in HEK293 cells expressing TLR2 but not in HEK293 cells expressing other TLRs (Fig. 3A). As expected, E. coli LPS activated NF-
B in cells expressing TLR4 and not other TLRs (Fig. 3A), and treatment of E. coli LPS (1 µg/ml) with polymyxin B (10 µg/ml) blocked NF-
B induction in TLR4-expressing cells (data not shown). Since rBspA preparations used in this study were treated with polymyxin B, the results confirm that the responses obtained with rBspA preparations were not due to residual LPS in the preparations that might have escaped detection.
![]() View larger version (37K): [in a new window] |
FIG. 3. (A) TLR2 and TLR1 recognize BspA. HEK293 cells were transiently transfected with plasmids expressing the indicated human TLRs or an empty vector (EVC). Cells were incubated for 6 h with zymosan (10 µg/ml), BspA (5 µg/ml), highly purified E. coli LPS (Ec LPS) (1 µg/ml), or no agonist. NF- B activity in supernatants was quantified by the luciferase reporter assay. (B) NF- B is activated by BspA through TLR2 and TLR1 but not through TLR2 and TLR6. Cells were transiently transfected with the TLR2 and TLR1 plasmids or with the TLR2 and TLR6 plasmids and incubated for 6 h with the indicated reagents. The data are the averages ± standard deviations for triplicate wells, normalized to the unstimulated cells for each TLR combination. Statistically significant cellular activation (P < 0.05) compared with the corresponding unstimulated control (A) or a statistically significant difference between TLR2/TLR1 and TLR2/TLR6 (B) as calculated by Student's t test is indicated by an asterisk. Pam3, Pam3Cys. (C) Anti-human TLR2 antibody (Ab) inhibited BspA-mediated activation of NF- B activity in HEK293 cells stably expressing human TLR2 and human TLR1. HEK293 (hTLR2/hTLR1) stable cells were transiently transfected with reporter plasmids, the firefly luciferase gene conjugated with NF- B promoters (NF- B-luc), and Renilla luciferase genes (R-luc). Cells were preincubated with anti-TLR2 MAb (TL2.1; 5 mg/ml) or an Ig isotype-matched control (IgG2a; 5 mg/ml) for 30 min before stimulation with Pam3Cys (1 µg/ml) or BspA (5 µg/ml). After 6 h of stimulation, supernatants were collected, and the NF- B activity in supernatants was quantified by a luciferase reporter assay. The data are the averages ± standard deviations for triplicate determinations. Statistically significant inhibition (P < 0.05) as calculated by Student's t test compared to the isotype control treatment is indicated by an asterisk. (D) HEK293 or HEK293 (hTLR2/hTLR1) cells were stimulated with BspA protein (5 µg/ml) for 16 h, and the amount of IL-8 released in the medium was determined by an ELISA. The data are the means ± standard deviations for triplicate determinations. Statistical significance (P < 0.05) as calculated by Student's t test is indicated by an asterisk.
|
B was determined. The combination of TLR2 with TLR1, but not the combination of TLR2 with TLR6, was found to significantly enhance the response of HEK293 cells to BspA (Fig. 3B). NF-
B was not activated in response to rBspA by transfection with either TLR1 or TLR6 alone (Fig. 3A). Zymosan and Pam3Cys were used as positive control agonists for the TLR2/TLR6 and TLR/TLR1 receptor combinations, respectively. The significant response to BspA in cells transfected with TLR2 alone was likely due to heterodimerization of recombinantly expressed TLR2 with endogenous TLR1, which is present at low levels in HEK293 cells.
The involvement of TLR2/TLR1 coreceptors in cellular activation by BspA was further confirmed using HEK293 cells stably expressing TLR2/TLR1 coreceptors [HEK293 (hTLR2/hTLR1) cells]. The results showed that anti-TLR2 MAb significantly blocked BspA-induced NF-
B activation in HEK293 (hTLR2/hTLR1) cells compared to activation with BspA alone or with rBspA in the presence of an isotype control antibody (Fig. 3C). Furthermore, the BspA protein induced secretion of IL-8 from HEK293 (hTLR2/hTLR1) cells but not from HEK293 cells (Fig. 3D). Additionally, to determine the function of the BspA protein in the context of the whole bacterial cell, we compared the TLR2/TLR1 activation abilities of the wild-type T. forsythia strain and its BspA mutant. The wild-type T. forsythia strain induced IL-8 secretion in HEK293 (hTLR2/hTLR1) cells. A BspA-defective T. forsythia mutant (BFM571) was found to be significantly less potent (P < 0.05) in terms of the ability to induce IL-8 secretion in these cells at a multiplicity of infection (MOI) of 20:1. However, at a higher MOI, there was no significant difference between the ability of the wild type to induce IL-8 and the ability of the mutant to induce IL-8 (Table 2). This is not surprising since other surface molecules, including homologs of BspA encoded in the T. forsythia genome, are likely to also be involved in TLR2 induction and thus may have compensatory functions. Moreover, surface lipoproteins in T. forsythia have previously been shown to activate TLR2 (10). Our results suggest that at a low MOI (i.e., at early stages of infection), BspA could play a significant role in the induction of TLR2-mediated proinflammatory responses. Interestingly, a recent study showed that the expression of BspA in T. forsythia is induced severalfold in vivo (35). Thus, estimation of the TLR2 induction by in vitro-grown T. forsythia cells and comparison with a BspA mutant as described above are likely to underestimate the true potential of BspA in host inflammation in vivo.
|
View this table: [in a new window] |
TABLE 2. Activation of TLR2 by T. forsythia parent strain ATCC 43037 and BspA mutant strain BFM571
|
![]() View larger version (10K): [in a new window] |
FIG. 4. BspA binds TLR2 but not CD14. (A) Binding of biotinylated BspA (10 µg/ml) to the indicated receptors was determined colorimetrically using receptor-coated microtiter wells probed with peroxidase-conjugated streptavidin. (B) Dose-response binding curve at the indicated concentrations of BspA. The data are means ± standard deviations of duplicate determinations in typical experiments, which were repeated three times with similar findings. BSA, bovine serum albumin.
|
B activation in HEK293 (hTLR2/hTLR1) stable cells. We used a His-tagged glutathione S-transferase fusion protein (His-GST) as a negative control. The results showed that rBspA, rBspLRR-1-2, and rBspLRR-1 significantly upregulated NF-
B activation compared to His-induced activation. However, the LRR-deficient recombinant derivative rBsp
LRR failed to significantly induce NF-kB activation compared to the His-GST control (Fig. 5). These studies demonstrated that LRR domain D1 of BspA is the primary region involved in TLR2 activation.
![]() View larger version (17K): [in a new window] |
FIG. 5. BspA LRR domain D1 activates TLR2/TLR1. HEK293 cells cotransfected with human TLR2 and human TLR1 plasmids along with the reporter plasmid were incubated with rBspA, rBspLRR-1-2, rBspLRR-1, rBsp LRR, or His-GST (negative control protein), each at a final concentration of 5 nM, for 6 h. The cells were harvested and lysed for further determination of NF- B activity. The data are expressed in relative luciferase units and are averages ± standard deviations for triplicate determinations, normalized to His-GST-treated cells (control). A statistically significant difference (P < 0.05) compared to the rBsp LRR or His-GST treatment as calculated by Student's t test is indicated by an asterisk.
|
|
|
|---|
We are also interested in identifying the BspA epitopes responsible for binding to TLR2 in the hope of deciphering common molecular peptide patterns recognized by TLRs. Since genes encoding BspA-like homologs have also been identified in several recently completed genomes of other oral pathogens (2), we predict that TLRs may be involved in recognition of these pathogens as well via BspA-like homologs. Interestingly, TLRs contain LRR domains in their extracellular ligand binding domains. The LRR domains have been implicated in protein-protein interactions (16, 17). Thus, we hypothesized that the LRR of BspA may be involved in the interaction with TLR2. This hypothesis was tested by determining the activity of truncated BspA derivatives in TLR2 activation. The results clearly demonstrated that LRR domain D1 of BspA is responsible for the NF-
B activation in HEK293 cells through TLR2. Although the mechanisms of their interactions remain to be elucidated, this finding implies that both LRR regions in the extracellular ligand binding domain of TLR2 and in BspA are likely to be involved in TLR2-mediated cellular activation in human epithelial cells.
Since oral epithelial cells represent the first line of host defense against oral bacterial challenge by triggering host innate and inflammatory responses important in recruiting neutrophils, BspA may have an important role in the pathogenesis of T. forsythia-induced periodontal diseases. While neutrophils function to clear oral pathogens at infected sites, they may also contribute to the destruction of the periodontium (20). In fact, neutrophils have recently been implicated as key players in host-mediated inflammatory tissue injury in periodontitis (34). It is possible that uncontrolled polymorphonuclear leukocyte recruitment may lead to the tissue destruction observed in periodontitis associated with T. forsythia. Moreover, since BspA is also secreted, it is likely to cause inflammation at sites distant from the site of bacterial colonization. Thus, our findings suggest that BspA is an important modulator of host innate immune responses through activation of TLR2 in cooperation with TLR1. It would also be of interest to determine if other BspA homologs identified in T. forsythia have overlapping roles by triggering TLRs to cause inflammatory responses.
This study was supported by grants from the NIDCR (grant DE014749 to A.S., grant DE015254 to G.H., and grant DE017384 to D.K.).
Published ahead of print on 29 October 2007. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»